Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

计划入组 310 人 · 首次发布于 2024 年 2 月 20 日

A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

计划入组 46 人 · 首次发布于 2025 年 5 月 2 日

Tau PET Outcomes With Anti-amyloid Immunotherapies

计划入组 135 人 · 首次发布于 2024 年 12 月 9 日

Anti-MTBR-Tau

Anti-Tau Antibody

anti-tau vectorized mAbs

Alpha Tau Medical

Israel

Novel Anti-Infective Technologies, LLC

AiCuris Anti-Infective Cures AG

Germany

Bristol Myers Squibb's Anti-Tau Antibody BMS-986446 Receives FDA Fast Track Designation for Alzheimer's Disease

UCL and Eisai Extend Neurodegenerative Disease Drug Discovery Partnership Through 2030

Eisai's Anti-MTBR Tau Antibody E2814 Shows Promise in Early Alzheimer's Disease